Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Information

v3.23.3
Balance Sheet Information
 9 Months Ended
Sep. 30, 2023
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Information Balance Sheet Information
Cash, Cash Equivalents and Restricted Cash
A summary of cash and cash equivalents and restricted cash is as follows:
September 30, 2023 December 31, 2022
Cash and Cash Equivalents $ 5,400,498  $ 5,964,556 
Restricted Cash, Non-current 4,031  49,260 
Total Cash, Cash Equivalents and Restricted Cash $ 5,404,529  $ 6,013,816 
Non-current restricted cash consists of deposits with financial institutions for corporate credit cards, and such amounts are included in prepaid expenses and other current assets.
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
September 30, 2023 December 31, 2022
Prepaid Insurance $ 116,853  $ 117,315 
Prepaid Research and Development 49,377  128,429 
Other 73,161  97,325 
Total Prepaid Expenses and Other Current Assets $ 239,391  $ 343,069 
Accrued Expenses
Accrued expenses consist of the following:
September 30, 2023 December 31, 2022
Payroll and Benefits $ 828,694  $ 1,312,443 
Professional Fees 68,819  282,721 
Clinical Trials 424,026  57,020 
Other 140,172  183,750 
Total Accrued Expenses $ 1,461,711  $ 1,835,934